Charles River Integrates Cell and Gene Therapy Acquisitions to Enhance End-to-End Offering for Developers

In March 2021, Cobra and Cognate officially joined the Charles River family and in January 2022, we launched the rebranding of our businesses into Charles River, also adding our online content and information to a new home on

Our acquisition by Charles River has been an incredible step for both our team and clients; with the benefit of a shared quality system, faster internal technical transfer, and process crossover between teams helping to reduce program bottlenecks and provide a seamless end-to-end experience, we are now uniquely positioned to help our clients accelerate and achieve critical development goals from discovery to commercialisation.

To learn more about what this means for you and our cell and gene therapy customers, please click here to read our newsletter.


More within